Drug intelligence / Profile preview

pegylated BA-210

Development stage: Unknown
Lead developer: BioAxone BioSciences
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
Administration: Topical

Overview

Pegylated BA-210 is a PEGylated version of BA-210, which is a first-in-class, topically applied, biologic Rho inhibitor. The original BA-210 was developed by BioAxone BioSciences to inactivate Rho. PEGylation (the addition of polyethylene glycol chains) is a common strategy to improve drug circulation time, reduce immunogenicity, and enhance therapeutic efficacy. The drug acts as a Rho GTPase inhibitor and ROCK1 (Rho-associated protein kinase 1) inhibitor, which may help in treating acute spinal cord injury by preventing neuronal damage.

Brand names: Praconase

Targets

Rho family (Rho family GTPases)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on pegylated BA-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pegylated BA-210.

Explore the full profile